Taft attorneys Steve Auten, Richard Ruzich, Joe Bennett-Paris and Brian Murray contributed chapters to the second edition of “Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio” which was published by ABA Publishing. The book is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that pharmaceutical litigants could follow. Auten and Ruzich also served as associate editors. For more information or to order the book, click here.
Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum,” which has more than 8,500 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in ANDA litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilar sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.
Bennett-Paris is a partner in Taft’s Pharmaceutical and Life Sciences Litigation practice. He counsels clients in all areas of patent law, including patent prosecution, non-infringement, patentability, freedom-to-operate, invalidity and licensing. His practice primarily focuses on biotechnology, pharmaceutical, chemistry, and most recently, biosimilars.
Murray has experience with a wide range of patents and technologies, such as pharmaceutical formulations including solid oral dosage formulations, ophthalmic formulations, inhalation aerosol formulations, parenteral formulations, and sustained-release technologies; medical devices including those for inhalation drug delivery; and polymorph characterization. He has participated in all facets of litigation, from fact and expert discovery matters to pre-trial and trial phases of federal and appellate litigation.